{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:05Z","timestamp":1792293545616,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ctrv.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T01:01:21Z","timestamp":1521248481000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions"],"prefix":"10.1016","volume":"66","author":[{"given":"Gonzalo","family":"Tapia Rico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Cehic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.03.002_b0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2018.03.002_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10555-011-9292-1","article-title":"Current knowledge on diagnosis and staging of neuroendocrine tumors","volume":"30","author":"Oberg","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2018.03.002_b0015","first-page":"637","article-title":"The malignant carcinoid syndrome","volume":"137","author":"Davis","year":"1973","journal-title":"Surgery, Gynecol Obstetrics"},{"key":"10.1016\/j.ctrv.2018.03.002_b0020","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0025","doi-asserted-by":"crossref","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 18, 525\u2013534.","DOI":"10.1016\/S1470-2045(17)30110-9"},{"key":"10.1016\/j.ctrv.2018.03.002_b0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10517-010-0821-7","article-title":"Clinical and biochemical aspects of the carcinoid syndrome in neuroendocrine tumors of the abdominal and retroperitoneal organs and its impact for the disease prognosis","volume":"148","author":"Polikarpova","year":"2009","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.ctrv.2018.03.002_b0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.03.002_b0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004836-200301000-00031","article-title":"Carcinoid crisis induced by external manipulation of liver metastasis","volume":"36","author":"Kharrat","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/bja\/87.3.447","article-title":"Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours","volume":"87","author":"Kinney","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ctrv.2018.03.002_b0050","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0003-4975(93)90696-F","article-title":"Carcinoid crisis after biopsy of a bronchial carcinoid","volume":"56","author":"Karmy-Jones","year":"1993","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2018.03.002_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-33-43","article-title":"Hepatic arterial embolization in patients with neuroendocrine tumors","volume":"33","author":"Del Prete","year":"2014","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"10.1016\/j.ctrv.2018.03.002_b0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)lu-dota(0), tyr(3)]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2018.03.002_b0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1445-5994.2012.02719.x","article-title":"Carcinoid crisis induced by repeated abdominal examination","volume":"42","author":"Morrisroe","year":"2012","journal-title":"Int Med J"},{"key":"10.1016\/j.ctrv.2018.03.002_b0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004311-199703540-00009","article-title":"Anesthesia for patients with carcinoid syndrome","volume":"35","author":"Vaughan","year":"1997","journal-title":"Int Anesthesiol Clin"},{"key":"10.1016\/j.ctrv.2018.03.002_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jclinane.2010.12.009","article-title":"Carcinoid syndrome and perioperative anesthetic considerations","volume":"23","author":"Mancuso","year":"2011","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.ctrv.2018.03.002_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjaceaccp\/mkq045","article-title":"Carcinoid: the disease and its implications for anaesthesia","volume":"11","author":"Powell","year":"2011","journal-title":"Continu Educ Anaesthesia Crit Care Pain"},{"key":"10.1016\/j.ctrv.2018.03.002_b0085","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.7314\/APJCP.2014.15.16.6679","article-title":"Somatostatin analogues do not prevent carcinoid crisis","volume":"15","author":"Guo","year":"2014","journal-title":"Asian Pacific J Cancer Prevent: APJCP"},{"key":"10.1016\/j.ctrv.2018.03.002_b0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.surg.2015.05.036","article-title":"Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis","volume":"159","author":"Condron","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2018.03.002_b0095","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12630-012-9879-1","article-title":"Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review","volume":"60","author":"Seymour","year":"2013","journal-title":"Can J Anaesthesia=J Can d'anesthesie"},{"key":"10.1016\/j.ctrv.2018.03.002_b0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00001622-200201000-00010","article-title":"Somatostatin and somatostatin analogues: diagnostic and therapeutic uses","volume":"14","author":"de Herder","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0026-0495(90)90214-W","article-title":"Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins","volume":"39","author":"Patel","year":"1990","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.ctrv.2018.03.002_b0110","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.ctrv.2018.03.002_b0115","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1634\/theoncologist.2016-0305","article-title":"The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review","volume":"22","author":"Michael","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.03.002_b0125","doi-asserted-by":"crossref","DOI":"10.1159\/000461583","article-title":"Enets consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2018.03.002_b0130","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Neuroendocrine Tumors Version 3.2017 - June 13, 2017. NCCN.org Available at <https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf>."},{"key":"10.1016\/j.ctrv.2018.03.002_b0135","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2018.03.002_b0140","first-page":"1184","article-title":"Emerging indications for octreotide therapy, part 1","volume":"51","author":"Mosdell","year":"1994","journal-title":"Am J Hospital Pharmacy"},{"key":"10.1016\/j.ctrv.2018.03.002_b0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2018.03.002_b0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide lar and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","article-title":"Development of effective prophylaxis against intraoperative carcinoid crisis","volume":"32","author":"Woltering","year":"2016","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.ctrv.2018.03.002_b0160","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2011-0372","article-title":"Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications","volume":"17","author":"Lewis","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2018.03.002_b0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0033-1333651","article-title":"Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases","volume":"30","author":"Gupta","year":"2013","journal-title":"Seminars Intervent Radiol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00261-004-0258-4","article-title":"Radiofrequency ablation of neuroendocrine liver metastases: the middlesex experience","volume":"30","author":"Gillams","year":"2005","journal-title":"Abdom Imag"},{"key":"10.1016\/j.ctrv.2018.03.002_b0175","first-page":"143","article-title":"Carcinoid crisis 24 hours after bland embolization: a case report","volume":"4","author":"Fujie","year":"2010","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ctrv.2018.03.002_b0180","first-page":"1074","article-title":"Intraoperative carcinoid hypertensive crisis precipitated by yttrium 90 microsphere radioembolotherapy","volume":"16","author":"Ahuja","year":"2010","journal-title":"Endocrine Practice: Official J Am College Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0971-3026.111478","article-title":"A pictoral review on somatostatin receptor scintigraphy in neuroendocrine tumors: the role of multimodality imaging with srs and glut receptor imaging with fdg pet-ct","volume":"22","author":"Shah","year":"2012","journal-title":"Indian J Radiol Imag"},{"key":"10.1016\/j.ctrv.2018.03.002_b0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"10.1016\/j.ctrv.2018.03.002_b0195","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0200","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177lu-dota 0, tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.03.002_b0205","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0001-2998(95)80016-6","article-title":"Therapy of neuroendocrine tumors with radiolabeled mibg and somatostatin analogues","volume":"25","author":"Wiseman","year":"1995","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ctrv.2018.03.002_b0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2018.03.002_b0215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/BF03344149","article-title":"Carcinoid crisis induced by receptor radionuclide therapy with 90y-dotatoc in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)","volume":"29","author":"Davi","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ctrv.2018.03.002_b0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment dotatate y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (gep-nets): a phase ii study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol\/ESMO"},{"key":"10.1016\/j.ctrv.2018.03.002_b0225","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/bjc.2013.103","article-title":"Peptide receptor radionuclide therapy with (90)y-dotatate\/(90)y-dotatoc in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity","volume":"108","author":"Vinjamuri","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.03.002_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Fr\u00f6jd","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ctrv.2018.03.002_b0235","doi-asserted-by":"crossref","DOI":"10.1159\/000475526","article-title":"Enets consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2018.03.002_b0240","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","article-title":"Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2018.03.002_b0245","unstructured":"https:\/\/www.aci.health.nsw.gov.au\/__data\/assets\/pdf_file\/0004\/255451\/NSW-Lutate-therapy-referral-protocol-2017.pdf."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721830029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721830029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T01:34:15Z","timestamp":1570930455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721830029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":49,"alternative-id":["S030573721830029X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.03.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}